Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q4 FY20 results · Jan–Mar 2020
Natco Pharma reported revenue from operations of ₹454.80 crore (down 0.2% from Q4 FY19) and net profit of ₹93.20 crore (down 22.6% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 454.80 | 455.70 | −0.2% | 482.20 | −5.7% |
| Other income | 22.40 | 31.00 | −27.7% | 30.80 | −27.3% |
| Total income | 477.20 | 486.70 | −2.0% | 513.00 | −7.0% |
| Profit before tax | 116.70 | 152.40 | −23.4% | 128.80 | −9.4% |
| Net profit for the period | 93.20 | 120.40 | −22.6% | 104.40 | −10.7% |
| Attributable to shareholders of the company | 94.10 | 120.80 | −22.1% | 104.50 | −10.0% |
| EPS, basic (₹) | 5.17 | 6.59 | −21.5% | 5.75 | −10.1% |
| Net margin (%) | 20.5 | 26.4 | 21.7 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 420.10 | 416.30 | +0.9% | 447.70 | −6.2% |
| Other income | 38.60 | 30.70 | +25.7% | 30.90 | +24.9% |
| Total income | 458.70 | 447.00 | +2.6% | 478.60 | −4.2% |
| Profit before tax | 123.90 | 154.40 | −19.8% | 127.30 | −2.7% |
| Net profit for the period | 101.00 | 123.40 | −18.2% | 103.60 | −2.5% |
| EPS, basic (₹) | 5.55 | 6.73 | −17.5% | 5.70 | −2.6% |
| Net margin (%) | 24.0 | 29.6 | 23.1 |
Consolidated
- Filed with BSE
- 17 Jun 2020, 19:02 IST
- Board meeting
- 17 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Jun 2020, 19:02 IST
- Board meeting
- 17 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE